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 ABSTRACT
Introduction and Aims: Fibroblast growth factor 23 (FGF-23) induces phosphaturia. Its clinical impact is 
beyond mineral bone disease in chronic kidney disease (CKD), being coupled with vascular calcification and 
mortality. Residual renal function (RRF) is associated with significant capacity to excrete phosphate in peri-
toneal dialysis (PD). Besides testing whether FGF-23 is still related with glomerular filtration rate (GFR) and 
phosphate excretion in this late stage of CKD (5d), we aimed to explore its link with vascular calcification. 
Subjects and Methods: FGF-23 (C terminal) was measured in forty prevalent PD patients with RRF, aged 
61.5 (51.0-67.0) years old, in renal replacement therapy (RRT) for 43.5 (23-80.0) months; 36.6% were female, 
19.5% had diabetes mellitus and 37.5% were under automated PD regimen; 80% were on PD first, and 
only 20% had previous RRT. Relevant variables including dietary phosphate (P) intake, CKD- bone labora-
tory parameters, serum 25-hydroxyvitamin D, magnesium (Mg) levels, GFR, urinary phosphate, fractional 
excretion of phosphorus (FEP), albumin, proBNP and Adragão vascular calcification score were explored. 
Results: Median levels (25-75% range) of serum variables were: FGF-23 1997 (1623-2149) RU/mL, Mg 0.94 
(0.8-1.0) mmol/L, 25-hydroxyvitamin D 30 (18-47) nmol/L, calcium 2.2 (2.0-2.37) mmol/L, phosphorus 1.69 
(1.30-1.90) mmol/L, PTH 429 (309-626) pg/mL. FGF-23 correlated positively with serum phosphate (r = 0.39, 
p = 0.013) and negatively with urine volume (r = -0.48, p = 0.001), phosphaturia (r = -0.594, p < 0.0001) 
and GFR (r =-0.61, p < 0.0001). However, FGF-23 was not significantly correlated with age, total time of RRT, 
dietary P, FEP, Mg, nor 25-hydroxyvitamin D. High FGF-23 group had higher FEP. GFR was the single inde-
pendent predictor of increased FGF-23. On the other hand, neither FGF-23 nor low FEP/FGF-23 ratio were 
significantly associated with the vascular calcification score. Only albumin (lower), magnesium (lower) and 
proBNP (higher) levels significantly differed in calcified versus non-calcified patients (all with p < 0.05). 
aConclusions: In our population, FGF-23 was not associated with vascular calcification. GFR was the single 
independent predictor of increased FGF-23 in patients with diuresis. Increment of FGF-23 in PD patients 
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 INTRODUCTION
Fibroblast growth factor -23 (FGF-23) is a hormone 
whose main known function is the regulation of the 
phosphate concentration in plasma. It is secreted by 
osteocytes and acts on the kidneys, at the FGF recep-
tor (FGFR)-klotho complex, to increase the excretion 
of phosphate. The FGF-23 also inhibits the conversion 
of calcidiol (25[OH] vitamin D) to calcitriol (1.25[OH]2 
vitamin D)1. According with these actions, FGF-23 
induces phosphaturia and is responsible for a sig-
nificant part of phosphate metabolism and control2. 
In CKD, as urinary phosphate excretion declines FGF-
23 levels increase and can reach 1000-fold above 
signalizes an active endocrine phosphaturic process compensating renal function loss, as expressed by 
higher fractional excretion of phosphorus. It alerts for dietetic and therapy optimization. However, its link 
with vascular calcification still lacks validation.
Key-Words: FGF-23; fractional excretion of phosphorus; peritoneal dialysis; phosphaturia; residual renal 
function; vascular calcification.
 RESUMO
Introdução: O fator de crescimento do fibroblasto 23 (FGF-23) induz fosfatúria. A sua importância clínica 
ultrapassa o seu impacto na doença óssea da doença renal, associando-se, segundo alguns autores, à cal-
cificação vascular e à mortalidade. Nos doentes em diálise peritoneal (DP), a função renal residual (FRR) é 
responsável por uma fracção significativa da excreção do fósforo. O nosso objectivo foi testar se o FGF -23 
se relaciona com o débito do filtrado glomerular (DFG) e a excreção de fosfato nesta fase tardia da DRC(5d), 
focando a sua relação com calcificação vascular. Métodos: O FGF-23 (C terminal) foi medido em 40 doentes 
prevalentes em DP com função renal residual, com idade de 61.5 (51,0-67,0) anos, em tratamento substitutivo 
da função renal há 43,5 (23-80,0) meses. Destes doentes, 36,6% eram do sexo feminino 19,5 % tinham 
diabetes mellitus e 37,5% estavam sob regime de DP automática; 80% iniciaram diálise com DP; apenas 
20% estiveram previamente sob outra técnica substitutiva da função renal. Foram exploradas variáveis clínicas 
relevantes, nomeadamente fosfato dietético, parâmetros ósseos, 25-hidroxivitamina D, magnésio (Mg), DFG, 
fosfatúria, fração excrecional de fosfato (FEP), albumina, proBNP e o score de calcificação vascular de Adra-
gão. Resultados: Os valores medianos (IQ 25-75) das variáveis séricas foram: FGF-23 1997 (1623-2149) RU/
mL, Mg 0,9 (0,8-1,0) mmol/L, 25-hidroxivitamina D 30 (18-47) nmol/L, cálcio 2,2 (2,0-2,4) mmol/L, fósforo 1,7 
(1,3-1–,9) mmol/L, PTH 429 (309-626) pg/mL. O FGF-23 correlacionou-se positivamente com o fósforo sérico 
(r = 0,39, p = 0,013) e negativamente com o volume de urina (r = -0,48, p = 0,001), fosfatúria (r = -0,594, 
p < 0,0001) e DFG (r = -0,61, p < 0,0001). No entanto, não se verificou qualquer relação significativa com 
idade, tempo em terapêutica da substituição da função renal, fósforo dietético, FEP, Mg ou 25-hidroxivitamina 
D. O grupo com valor elevado de FGF-23 apresentava aumento da FEP. O DFG foi preditor independente de 
aumento do FGF-23. Por outro lado, nem o FGF-23 nem o rácio baixo FEP/FGF-23 se associaram significati-
vamente com o score de calcificação vascular. A albumina (baixa), o magnésio (baixo) e o proBNP (elevado) 
foram significativamente diferentes em doentes calcificados quando comparados com não calcificados (todos 
com p < 0,05). Conclusões: No nosso estudo não foi confirmada a associação do FGF-23 com a calcificação 
vascular. O DFG foi o único preditor independente do aumento de FGF-23 em doentes sob diálise peritoneal 
com função renal residual. O aumento do FGF-23 sinaliza um processo fosfatúrico ativo, compensatório face 
à perda de FRR, tal como é expresso pelo aumento da fracção excrecional de fósforo. Poderá alertar para 
oportuna optimização da dieta e da terapêutica no âmbito do metabolismo fosfocálcico. No entanto a sua 
associação com calcificação vascular permanece por validar.
Palavras-Chave: Calcificação vascular; diálise peritoneal; FGF-23; fosfatúria; fração excrecional de fósforo; 
função renal residual.
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normal in end stage renal disease (ESRD)3. In recent 
years, an association was reported between FGF-23 
and all-cause mortality, not only in people undergo-
ing dialysis4, but also in pre-dialysis patients5.
Hyperphosphatemia often occurs in dialysis 
patients and is an independent risk factor for arterial 
calcification, associated with cardiovascular events 
and mortality6. Residual renal function (RRF) is 
responsible for a significant capacity to excrete 
phosphate, therefore, FGF23 seems to be a key 
mediator of serum phosphorus levels control in 
patients with diuresis. However, the role for FGF-23 
in the process of progressive arterial calcification is 
not clear7.
Since the clinical impact of high FGF-23 
appears to be beyond mineral bone disease in 
CKD, its measurement may identify a different 
dimension of kidney function that is not fully 
captured by glomerular f iltration rate. Therefore, 
besides testing whether FGF-23 is still related 
with GFR and phosphate excretion in this late 
stage of CKD (5d), we aimed to explore its link 
with vascular calcif ication.
 SUBJECTS AND METHODS
 Study population:
We have studied 40 prevalent and stable patients 
aged 18 years or older who had been undergoing 
chronic peritoneal dialysis (continuous ambulatory 
peritoneal dialysis or continuous cyclic peritoneal 
dialysis) at the division of Nephrology at Centro 
Hospitalar do Porto, Portugal.
Inclusion criteria: To be included in the study the 
patients had to be on PD for at least 3 months and 
have residual renal function (as measured by diuresis 
> 100mL/day). The clinical characteristics and labora-
tory data of our 40 patients treated with peritoneal 
dialysis are summarized in Table I.
 Data collection and measurements:
We have analysed the following data that was 
collected at a single random visit to the peritoneal 
dialysis centre: demographic characteristics, 
medical history, smoking status, use of active 
vitamin D analogues, cinacalcet or oral phosphate 
binders, dose of dialysis, GFR, and blood and uri-
nary samples. Comprehensive metabolic panels and 
urinary biochemical panels were measured using 
standard assays. A dietary inquiry was done and 
the ingested daily amount of phosphate was cal-
culated. The peritoneal clearance of phosphate was 
measured.
Urinary fractional excretion of phosphate (FEP) 
was calculated as follows: [urine phosphorus (mg/
dl)/serum phosphorus (mg/dl)] × [serum creatinine 
(mg/dl)/urine creatinine (mg/dl)] × 100.
Plasma FGF-23 was measured using the second 
generation C-terminal assay. Samples were immedi-
ately centrifuged, aliquoted, and stored at -80 ºC 
until batched assays were performed. We have also 
applied the Adragão vascular calcification score8 at 
32 patients after excluding those who missed 
appointment for radiological testing. Adragão et al.8 
showed that vascular calcification score ≥3 is the 
best cut-off value associated with cardiovascular 
mortality and cardiovascular events, reason why we 
used that value to dictate a positive vascular score. 
All tests and radiographic films of pelvis and hands 
Table I
Clinical characteristics and laboratory data of participants
Patients (n = 40)
Female sex 36.6%
Diabetes mellitus 19.5%
Automated peritoneal dialysis (APD) 37.5%
Treatment
Vitamin D analogues
Calcium carbonate
Sevelamer
Cinacalcet
85.0%
31.7%
63.4%
29.3%
Age (years) 61.5 (51.0 – 67.0)
Time on PD (months) 43.5 (23.0 – 80.0)
Magnesium (mmol/L) 0.94 (0.85 – 1.0)
25-hydroxyvitamin D (nmol/L) 30 (18 – 47)
Calcium (mmol/L) 2.2 (2.0 – 2.37)
Phosphate (mmol/L) 1.69 (1.30 – 1.90)
PTH (pg/mL) 429 (309 – 626)
Albumin (g/L) 4.01 (3.78 – 4.22)
ProBNP (pg/mL) 1637 (556 – 4358)
Urine volume (mL) 1000 (537-1400)
Urine phosphate (mmol/day) 6.21 (4-11.47)
FEP (%) 64 (54-79)
GFR (mL/min) 3 (0.9-5.6)
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were performed and blindly classified with Adragão 
score by a single investigator, at Centro Hospitalar 
do Porto, Portugal.
 Statistical analysis:
We used standard descriptive statistics to assess 
clinical and laboratory data at baseline. Continuous 
variables were summarized as median and inter-
quartile range (IQR). Categorical variables were 
expressed as frequencies and proportions. All vari-
ables were explored cross-sectionally. Pearson or 
Spearmen correlations were used as appropriate. 
Mann-Whitney U test was used to investigate vari-
ables in subgroups.
The FGF-23 variable was categorized as FGF-23 
tertile (below or above 1800 RU/ml) and investigated 
by multivariable logistic regression. For all compari-
sons, a p-value < 0.05 was considered statistically 
significant.
 RESULTS
  Associations of demographic, clinical, and laboratory 
characteristics with FGF-23:
The median concentration and IQ25-75 of immu-
noreactive FGF-23 was 1997 (1623 – 2149) reference 
units (RU/ml).
The FGF-23 correlated positively with serum phos-
phate (r = 0.39, p = 0.011) and negatively with urine 
volume (r = -0.48, p = 0.002), phosphaturia (r = 
-0.594, p < 0.0001) and GFR (r =- 0.57, p < 0.0001). 
However FGF-23 was not significantly correlated with 
age, time on dialysis, dietary phosphate ingestion, 
FEP, Mg, nor 25-hydroxyvitamin D.
We present the variables in subgroups categorized 
according to FGF-23 30% tertile (Table II).
The high FGF-23 levels group presented significan-
tly lower GFR, higher serum phosphate and higher 
urinary fractional excretion of phosphate (Fig. 1).
Multivariable logistic regression showed that GFR 
was the sole independent predictor of FGF-23. Each 
1 ml/min decrease in GFR was associated with a 90% 
chance of having higher FGF-23 (OR 1.898 (1.226-
2.939), p = 0.004).
 FGF-23 and arterial calcification
Radial and digital calcifications were present in 
19 patients (59.4%) and iliac and femoral calcifica-
tions were present in 21 patients (65.6%).
The distribution of vascular calcification score in 
the 32 patients was the following: score 0 in nine 
patients (28.1%), score 1 in one patient (3.1%), 
score 2 in four patients (12.5%), score 3 in seven 
Table II
Clinically relevant variables between high (> 1800RU/mL) versus low (< 1800RU/ml) FGF-23 groups
Low FGF-23
n = 12
High FGF-23
n=28
p-value
Age (years) 63.0 (58.0-66.8) 60.5 (48.5-69.5) 0.478
Time on dialysis (months) 43.5 (17.8-293.8) 43.5 (24.8-74.8) 0.941
Diet P (mg/day) 1044 (905-1490) 1233(1032-1389) 0.61
Serum phosphate (mmol/L) 1.32 (1.17-1.79) 1.74 (1.38-2.03) 0.013
Urine volume (mL) 1450 (1300-2375) 700 (400-1175) <0.001
Phosphaturia (mmol/day) 13.32 (7.25-18.16) 4.99 (1.85-7.35) <0.001
FEP % 57.6 (51.3-71.9) 68.6 (58.2-82.2) 0.077
GFR (ml/min) 6.33 (4.99-9.18) 2.14 (0.53-3.14) <0.001
Mg (mmol/L) 0.90 (0.85-0.96) 0.98 (0.84-1.05) 0.101
25-hydroxivitamin D (nmol/L) 30.0 (17.0-31.0) 30.5 (18.0-51.8) 0.593
PTH (pg/mL) 446.0 (327.3-521.7) 418.4 (284.3-690.8) 0.836
Peritoneal P clearance (L/week) 28 (25.7-38) 36.5(32.4-43) 0.09
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patients (22.0%), score 4 in five patients (15.6%), 
score 5 in one patient (3.1%), score 6 in three 
patients (9.4%) and score 7 and 8 both in one 
patient (each 3.1%).
The comparison between patients with positive 
vascular calcification score (score ≥ 3) versus low 
calcified patients showed that FGF-23 and low FEP/
FGF-23 were not significantly associated with vascu-
lar calcification.
By exploring subgroups with the Mann-Whitney 
U test only albumin (lower levels, p = 0.046), pro-
BNP (higher levels, p = 0.005) and magnesium 
(lower levels, p = 0.026) significantly differed 
between calcified (score ≥ 3) versus non-calcified 
group of patients (Fig. 2).
Figure 1
Graphical presentation of clinically significant variables distribution in subgroups according to the 30% tertile of FGF23: higher (> 1800 RU/mL) vs. lower (< 1800 RU/mL) 
FGF 23 groups (A – serum phosphate; B – GFR; C – fractional excretion of phosphorus).
 
Figure 2
Graphical presentation of differences of magnesium levels between calci-
fied (score ≥ 3) vs. non-calcified group of patients
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 DISCUSSION
The results of this cross-sectional study confirm 
that FGF-23 levels are markedly elevated in patients 
with ESRD and are associated with hyperphospha-
temia, but were not associated with vascular calci-
fication. Previous studies sustain the use of FGF-23 
as a stable biomarker of disordered phosphate 
metabolism9. Our study also showed that lower GFR 
determine higher FGF-23 levels. Indeed the amount 
of FGF-23 increases dramatically in dialysis patients. 
Data on FGF-23 levels in patients undergoing PD is 
limited. Isakova et al.9 showed that among PD adults 
with residual renal function, there is a continuous 
relationship between higher FGF-23 and lower resi-
dual renal function. However, we did not find any 
association between dialysis vintage and higher 
FGF-23. The limited number of patients that had 
previous RRT comparing to those on PD first (80%) 
did not allow to reliably test if FGF23 is significantly 
increased in patients with previous haemodialysis 
course of time.
There is still a lack of understanding on the 
determinants of FGF-23 serum concentrations. This 
issue was recently revised by the Frazão group10 and 
dietary phosphate has been pointed as a putative 
predictor. We were unable to document a significant 
difference in ingested phosphate load between the 
groups, but our population had high phosphate 
ingestion (1000-1400 mg/day), above the recommen-
ded target of 800-1000 mg/day, effacing the oppor-
tunity to test this hypothesis. This, however, remains 
a relevant issue in a population of dialysis patients 
prone to progressively loose renal capability to 
excrete ingested phosphate load. However, the 
phosphaturic action of FGF-23 is signalized by the 
higher phosphate fractional excretion present in the 
high FGF-23 group.
In early CKD progression FGF-23 is elevated well 
before serum phosphate levels are increased11 and 
is not correlated with PTH. The FGF-23 also presents 
a more stable laboratory profile and less intra-
-individual variability than PTH12 being an opportune 
tool to signalize the patient who may benefit from 
dietary counseling, dialysis optimization or higher 
dose of phosphate chelating agents.
We have also showed that therapy was adequa-
tely adjusted to increase dialysis solute removal 
since peritoneal phosphate clearance was higher in 
patients with lower renal function. Additionally, we 
tested the link between FGF-23 and vascular calcifi-
cation. A low fractional excretion of phosphate/
FGF-23 ratio has been associated with severe abdo-
minal aortic calcification in stage 3 and 4 CKD13. 
But, in our population FGF-23 or low fractional 
excretion of phosphate/FGF-23 ratio were not signi-
ficantly associated with a positive vascular calcifica-
tion score: the modest sample of patients may have 
limited the ability to demonstrate significant diffe-
rences between calcified versus non-calcified groups. 
However, the results published in literature for 
vascular calcification also remain conflicting7, 14.
Interestingly our results suggest an association 
of hypomagnesemia and vascular calcification, as 
previously documented by other investigators15 
pointing that hypomagnesemia and high FGF-23 
levels were independent predictors of mitral valve 
calcification and intima-media-thickness in 150 dia-
betic patients with mild to moderate CKD. It is stated 
that magnesium antagonizes phosphate-induced 
apoptosis of vascular smooth muscle cells preven-
ting vascular calcification and it was shown that 
magnesium modifies the association between serum 
phosphate and the risk of progression to end-stage 
kidney disease in patients with non-diabetic chronic 
kidney disease16. The cellular pathways of magne-
sium interference with vascular calcification are 
presently under investigation17.
We acknowledge some limitations in our study, 
particularly dependent on the small sample of enrolled 
patients and the cross-sectional design. Methodologi-
cal skills also need to be optimized since the measu-
rement of FGF-23 is still investigational: the reagents 
in 2nd generation human FGF-23 ELISA kit have been 
optimized, so that the high dose “hook effect” is not 
a problem for samples with elevated FGF-23 values. 
Samples with levels between the highest standard and 
750,000 RU/mL will read greater than the highest 
standard and were diluted 1:10 or greater with the 0 
RU/mL calibrator. But dilution of high-reading samples 
with saline may result in significant deviation from 
linearity. Besides current ELISA kits for plasma intact 
FGF-23 measurement show poor analytical agreement 
and cannot be used interchangeably18.
There is a scarce number of studies addressing 
the pathophysiological axis of FGF-23 in peritoneal 
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dialysis, therefore, it seems to us that the present 
study is opportune and points to investigational 
tracks such as the link between magnesium and 
vascular calcification. Longitudinal design will be 
mandatory to clarify other putative determinants 
of FGF-23 and its ultimate clinical impact on PD 
patients.
 CONCLUSIONS
Fibroblast growth factor 23 was not associated 
with vascular calcification in our population. Glo-
merular filtration rate was the single independent 
predictor of increased FGF-23 on PD patients with 
significant RRF. Increment of FGF-23 in PD patients 
signalizes an active endocrine phosphaturic pro-
cess compensating renal function loss as expressed 
by higher fractional excretion of phosphorus. It 
alerts for dietetic and therapy optimization. Howe-
ver, its link with vascular calcification still lacks 
validation.
Conflicts of interest statement: None declared.
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